Breast cancer is a complex disease that still imposes a significant healthcare burden on women worldwide. The etiology of breast cancer is not known but significant advances have been made in the area of early detection and treatment. The advent of advanced molecular biology techniques, mapping of the human genome and availability of high throughput genomic and proteomic strategies opens up new opportunities and will potentially lead to the discovery of novel biomarkers for early detection and prognostication of breast cancer. Currently, many biomarkers, particularly the hormonal and epidermal growth factor receptors, are being utilized for breast cancer prognosis. Unfortunately, none of the biomarkers in use have sufficient diagnostic, prognostic and/or predictive power across all categories and stages of breast cancer. It is recognized that more useful information can be generated if tumors are interrogated with multiple markers. But choosing the right combination of biomarkers is challenging, because 1) multiple pathways are involved, 2) up to 62 genes and their protein products are potentially involved in breast cancer-related mechanisms and 3) the more markers evaluated, the more the time and cost involved. This review summarizes the current literature on selected biomarkers for breast cancer, discusses the functional relationships, and groups the selected genes based on a Gene Ontology™ classification.
FordD., EastonD.F., StrattonM.. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet1998; 62: 676–89.
3.
LeinsterS.J., DowneyH., GibbsT.J.Shared care for breast disease.Oxford, UK: Isis Medical Media Ltd., 2000; 125.
4.
RubinsteinW.S.The genetics of breast cancer. In: VogelV.G., ed. Management of patients at high risk for breast cancer.Malden, MA: Blackwell Science, 2001.
5.
DowsettM., CookeT., EllisI.. Assessment of HER2 status in breast cancer: why, when and how?Eur J Cancer2000; 36: 170–6.
6.
SlamonD.J., ClarkG.M., WongS.G., LevinW.J., UllrichA., McGuireW.L.Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science1987; 235: 177–82.
7.
PressM.F., JonesL.A., GodolphinW., EdwardsC.L., SlamonD.J.HER-2/neu oncogene amplification and expression in breast and ovarian cancers. Prog Clin Biol Res1990; 354A: 209–21.
8.
AllredD.C., ClarkG.M., MolinaR.. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol1992; 23: 974–9.
9.
WiltschkeC., Kindas-MueggeI., SteiningerA., ReinerA., ReinerG., PreisP.N.Co-expression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients. J Cancer Res Clin Oncol1994; 120: 737–42.
10.
IshikawaT., KobayashiM., MaiM., SuzukiT., OoiA.Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Path1997; 151: 761–8.
11.
van de VijverM.J.Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). Eur J Cancer2001; 37(Suppl 1): 11–7.
12.
CookeT., ReevesJ., LanniganA., StantonP.The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. Eur J Cancer2001; 37(Suppl 1): 3–10.
13.
VenterJ.C., AdamsM.D., MyersE.W.. The sequence of the human genome. Science2001; 291: 1304–51.
14.
CollinsF.S., MorganM., PatrinosA.The human genome project: lessons from large-scale biology. Science2003; 5617: 286–90.
15.
AlbertiS.Preface: Workshop “Emerging molecular markers in oncology: Focused therapy, indicators of response, chemoprevention”. Int J Biol Markers2003; 18: 35.
16.
EtzioniR., UrbanN., RamseyS.. The case for early detection. Nat Rev Cancer2003; 3: 243–52.
17.
LippmanM.E., AllegraJ.C.Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer1980; 46(12 Suppl): 2829–34.
18.
CowleyS.M., HoareS., MosselmanS., ParkerM.G.Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem1997; 272: 19858–62.
19.
KatoS., KitamotoT., MasuhiroY., YanagisawaJ.Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways. Oncology1998; 55(Suppl 1): 5–10.
20.
KuiperG.G., CarlssonB., GrandienK.. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology1997; 138: 863–70.
21.
ClarkG.M., WengerC.R., BeardsleeS.. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer1993; 71(6 Suppl): 2157–62.
22.
GottardiO., BaiocchiC., FerrariM.. Correlation between histochemically assessed hormonal receptor content and clinical course in breast cancer. Presentation of 1,005 cases. Oncology1991; 48: 221–5.
23.
PichonM.F., MilgromE.Oestrogen receptor negative-progesterone receptor-positive phenotype in 1,211 breast tumours. Br J Cancer1992; 65: 895–7.
24.
TsangarisT.N., KnoxS.M., CheekJ.H.Tumor hormone receptor status and recurrences in premenopausal patients with node-negative breast carcinoma. Cancer1992; 69: 984–7.
25.
FisherB., RedmondC., FisherE.R., CaplanR.Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project protocol B 06. J Clin Oncol1988; 6: 1076–87.
26.
ElledgeR.M., McGuireW.L., OsborneC.K.Prognostic factors in breast cancer. Semin Oncol1992; 19: 244–53.
27.
FisherB., RedmondC., BrownA.. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol1983; 1: 227–41.
28.
HilfR., FeldsteinM.L., GibsonS.L., SavlovE.D.The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer1980; 45: 1993–2000.
29.
RaemaekersJ.M., BeexL.V., PietersG.F., SmalsA.G., BenraadT.J., KloppenborgP.W.Progesterone receptor activity and relapse-free survival in patients with primary breast cancer: The role of adjuvant chemotherapy. Breast Cancer Res Treat1987; 9: 191–9.
30.
AndersenJ.Determination of estrogen receptors in paraffin-embedded tissue. Techniques and the value in breast cancer treatment. Acta Oncol1992; 31: 611–27.
31.
RavdinP.M., GreenS., DorrT.M.. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J Clin Oncol1992; 10: 1284–91.
32.
PaoneJ.F., AbeloffM.D., EttingerD.S., ArnoldE.A., BakerR.R.The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast. Surg Gynecol Obstet1981; 152: 70–4.
33.
StuartN.S., PhilipP., HarrisA.L.. High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. Br J Cancer1992; 66: 833–9.
34.
LinV.C., NgE.H., AwS.E.. Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. Clin Cancer Res1999; 5: 395–403.
35.
LinV.C., NgE.H., AwS.E., TanM.G., NgE.H., BayB.H.Progesterone induces focal adhesion in breast cancer cells MDA-MB-231 transfected with progesterone receptor complementary DNA. Mol Endocrinol2000; 14: 348–58.
36.
BernouxA., de CremouxP., Laine-BidronC., MartinE.C., AsselainB., MagdelénatH.Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group. Breast Cancer Res Treat1998; 49: 219–25.
37.
BalleineR.L., EarlM.J., GreenbergM.L., ClarkeC.L.Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer1999; 79: 1564–71.
38.
MaiG.F., ZhengH., LuoR.C., LiaoW.J., ZhangL.S., HeX.B.Association of progesterone receptor and HER2 expressions with the survival time of patients with breast cancer. Di Yi Jun Yi Da Xue Xue Bao2003; 4: 372–4.
39.
PintoA.E., AndréS., MendonçaE., SilvaG., SoaresJ.Overall survival in advanced breast cancer: Relevance of progesterone receptor expression and DNA ploidy in fine-needle aspirates of 392 patients. Int J Biol Markers2003; 18: 7–12.
40.
SchneiderJ., PollanM., TejerinaA., SanchezJ., LucasA.R.Accumulation of uPA-PAI-1 complexes inside the tumor cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer. Br J Cancer2003; 88: 96–101.
41.
CoussensL., Yang-FengT.L., LiaoY.C.. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science1985; 230: 1132–9.
42.
MüllerV., ThomssenC., KarakasC.. Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay. Int J Biol Markers2003; 18: 13–20.
43.
ShihC., PadhyL.C., MurrayM., WeinbergR.A.Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature1981; 290: 261–4.
44.
LiuE., ThorA., HeM., BarcosM., LjungB.M., BenzC.The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene1992; 7: 1027–32.
45.
ChazinV.R., KalekoM., MillerA.D., SlamonD.J.Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene1992; 7: 1859–66.
46.
RohH., PippinJ.A., GreenD.W.. HER2/neu anti-sense targeting of human breast carcinoma. Oncogene2000; 19: 6138–43.
47.
BaselgaJ., TripathyD., MendelsohnJ.. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol1999; 26(4 Suppl 12): 78–83.
48.
SeidmanA.D., FornierM.N., EstevaF.J.. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol2001; 19: 2587–95.
49.
SlamonD.J., Leyland-JonesB., ShakS.. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med2001; 344: 783–92.
50.
Piccart-GebhartM.J.Herceptin: the future in adjuvant breast cancer therapy. Anticancer Drugs2001; 12(Suppl 4): S27–33.
51.
PressM.F., BernsteinL., ThomasP.A.. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol1997; 5: 2894–904.
52.
ClarkG.M.Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?J Natl Cancer Inst1998; 90: 1320–1.
53.
HerzH., CookeB., GoldsteinD.Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: case report and review of the literature. Ann Oncol2000; 11: 1343–7.
54.
PawlowskiV., RevillionF., HebbarM., HornezL., PeyratJ.P.Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res2000; 6: 4217–25.
55.
RossJ.S., FletcherJ.A.The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells1998; 16: 413–28.
56.
ZhangF., YangY., SmithT.. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer2003; 97: 1758–65.
57.
ElledgeR.M., AllredD.C.Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat1998; 52: 79–98.
58.
HermekingH., LengauerC., PolyakK.. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell1997; 1: 3–11.
59.
ZhangH., XiongY., BeachD.Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell1993; 4: 897–906.
60.
MirzaA., McGuirkM., HockenberryT.N.. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene2002; 21: 2613–22.
61.
HoffmanW.H., BiadeS., ZilfouJ.T., ChenJ., MurphyM.Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem2002; 277: 3247–57.
62.
DavidoffA.M., KernsB.J., IglehartJ.D., MarksJR. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res1991; 51: 2605–10.
63.
AllredD.C., ClarkG.M., ElledgeR.. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst1993; 85: 200–6.
64.
ThorA.D., MooreDHII, EdgertonS.M.. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst1992; 84: 845–55.
65.
EllisP.E., FongL.F., RolfeK.J.. The role of p53 and Ki67 in Paget's disease of the vulva and the breast. Gynecol Oncol2002; 86: 150–6.
66.
ElledgeR.M., GreenS., HowesL.. BCL-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol1997; 15: 1916–22.
67.
StalO., Stenmark AskmalmM., WingrenS.. p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol1995; 34: 767–70.
68.
ElledgeR.M., GrayR., MansourE.. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst1995; 87: 1254–6.
69.
DegeorgesA., de RoquancourtA., ExtraJ.M.. Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?Breast Cancer Res Treat1998; 47: 47–55.
70.
HenselM., SchneeweissA., SinnH.P.. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int J Cancer2002; 100: 290–6.
71.
GuerraE., VaccaG., PalomboB., AlbertiS.Prognostic value of mutations IN TP53 and RAS gene in breast cancer. Int J Biol Markers2003; 18: 49–53.
72.
BarnesD.M., GillettC.E.Cyclin D1 in breast cancer. Breast Cancer Res Treat1998; 52: 1–15.
73.
CaseyG., SmithR., McGillivrayD., PetersG., DicksonC.Characterization and chromosome assignment of the human homolog of int-2, a potential proto-oncogene. Mol Cell Biol1986; 6: 502–10.
74.
LammieG.A., FantlV., SmithR.. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene1991; 6: 439–44.
75.
GillettC., FantlV., SmithR.. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res1994; 54: 1812–7.
76.
BuckleyM.F., SweeneyK.J., HamiltonJ.A.. Cyclin A expression in normal and transformed alveolar epithelial cells. Oncogene1993; 8: 2127–33.
77.
SeshadriR., LeeC.S., HuiR., McCaulK., HorsfallD.J., SutherlandR.L.Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res1996; 2: 1177–84.
78.
BarbareschiM., PelosioP., CaffoO.. Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. Int J Cancer1997; 74: 171–4.
79.
BiecheI., OliviM., NoguesC., VidaudM., LidereauR.Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer2002; 86: 580–6.
80.
ChenY., FarmerA.A., ChenC.F., JonesD.C., ChenP.L., LeeW.H.BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res1996; 56: 3168–72.
81.
NahtaR., InglehartJ.D., KempkesB., SchmidtE.V.Rate-limiting effects of cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res2002; 62: 2267–71.
82.
PuschO., SoucekT., WawraE., Hengstschlager-OttnadE., BernaschekG., HengstschlagerM.Specific transformation abolishes cyclin D1 fluctuation throughout the cell cycle. FEBS Lett1996; 385: 143–8.
83.
AtadjaP., WongH., VeilleteC., RiabowolK.Overexpression of cyclin D1 blocks proliferation of normal diploid fibroblasts. Exp Cell Res1995; 217: 205–16.
84.
FantlV., StampG., AndrewsA., RosewellI., DicksonC.Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev1995; 9: 2364–72.
85.
SicinskiP., DonaherJ.L., ParkerS.B.. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell1995; 82: 621–30.
86.
McIntoshG.G., AndersonJ.J., MiltonI., StewardM., ParrA.H., ThomasM.D.Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene1995; 11: 885–91.
87.
MichalidesR., HagemanP., van TinterenH.. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer1996; 73: 728–34.
88.
PelosioP., BarbareschiM., BonoldiE.. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann Oncol1996; 7: 695–703.
89.
GillettC., SmithP., GregoryW.. Cyclin D1 and prognosis in human breast cancer. Int J Cancer1996; 69: 92–9.
90.
NielsenN.H., EmdinS.O., CajanderJ., LandbergG.Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene1997; 14: 295–304.
91.
Weinstat-SaslowD., MerinoM.J., ManrowR.E.. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med1995; 1: 1257–60.
92.
Van DiestP.J., MichalidesR.J., JanninkL.. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Path1997; 150: 705–11.
SutherlandR.L., PrattO.W.J., AlleK.M.. Cyclin dependent kinases as downstream targets of estrogen action: potential prognostic indicators and therapeutic targets. Endocr Relat Cancer1997; 4: 357–70.
95.
NeumanE., LadhaM.H., LinN.. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol1997; 17: 5338–47.
96.
WilckenN.R., PrallO.W., MusgroveE.A., SutherlandR.L.Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of anti-estrogens. Clin Cancer Res1997; 3: 849–54.
97.
UmekitaY., OhiY., SagaraY., YoshidaH.Overexpression of cyclinD1 predicts poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer2002; 98: 415–8.
98.
CatzavelosC., BhattacharyaN., UngY.C.. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med1997; 3: 227–30.
99.
PorterP.L., MaloneK.E., HeagertyP.J.. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med1997; 3: 222–5.
100.
TanP., CadyB., WannerM.. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive carcinomas. Cancer Res1997; 57: 1259–63.
101.
FredersdorfS., BurnsJ., MilneA.M.. High level expression of p27 (kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA1997; 94: 6380–5.
102.
KellnerU., RudolphP., ParwareschR.Human DNA-topoisomerases - diagnostic and therapeutic implications for cancer. Onkologie2000; 23: 424–30.
103.
ChampouxJ.J.Mechanism of the reaction catalyzed by the DNA untwisting enzyme: attachment of the enzyme to 3′-terminus of the nicked DNA. J Mol Biol1978; 118: 441–6.
104.
MaxwellA., GellertM.Mechanistic aspects of DNA topoisomerases. Adv Protein Chem1986; 38: 69–107.
105.
OsheroffN.Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol Ther1989; 41: 223–41.
106.
MillerK.G., LiuL.F., EnglundP.T.A homogeneous type II DNA topoisomerase from HeLa cell nuclei. J Biol Chem1981; 256: 9334–9.
107.
Tsai-PflugfelderM., LiuL.F., LiuA.A.. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA1988; 85: 7177–81.
108.
WoessnerR.D., MatternM.R., MirabelliC.K., JohnsonR.K., DrakeF.H.Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ1991; 2: 209–14.
109.
BoegeF., AndersenA., JensenS., ZeidlerR., KreipeH.Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies. Am J Path1995; 146: 1302–8.
110.
ChenA.Y., LiuL.F.DNA topoisomerases: essential enzymes and lethal targets. Ann Rev Pharmacol Toxicol1994; 34: 191–218.
111.
RocaJ., WangJ.C.DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell1994; 77: 609–16.
112.
IsaacsR.J., DaviesS.L., WellsN.J., HarrisA.L.Topoisomerase II alpha and beta as therapy targets in breast cancer. Anticancer Drugs1995; 6: 195–211.
113.
IsaacsR.J., DaviesS.L., SandriM.I., RedwoodC., WellsN.J., HicksonI.D.Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta1998; 1400: 121–37.
114.
WangQ., ZambettiG.P., SuttleD.P.Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor. Mol Cell Biol1997; 17: 389–97.
115.
NakopouloL., KatsarouS., GiannopoulouI.. Correlation of TIMP-2 with proliferative activity and patients’ survival in breast cancer. Mod Path2002; 15: 26–34.
116.
VillmanK., StahlE., LiljegrenG., TidefeltU., KarlssonM.G.Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas. Mod Pathol2002; 15: 486–91.
117.
ShpitzB., BomsteinY., ZehaviT.. Topoisomerase II alpha expression in ductal carcinoma in situ of the breast: A preliminary study. Hum Pathol2000; 31: 1249–54.
118.
LynchB.J., GuineeD.G., HoldenJ.A.Human DNA topoisomerase II-alpha: A new marker of cell proliferation in invasive breast cancer. Hum Pathol1997; 28: 1180–8.
119.
SampsonS.A., KreipeH., GillettC.E.. KiS1, a novel monoclonal antibody that recognizes proliferating cells: Evaluation of its relationship to prognosis in mammary carcinoma. J Pathol1992; 168: 179–85.
120.
SmithK., HoulbrookS., GreenallM., CarmichaelJ., HarrisA.L.Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene1993; 8: 933–8.
121.
DepowskiP.L., RosenthalS.I., BrienT.P., StylosS., JohnsonR.L., RossJ.S.Topoisomerase II alpha expression in breast cancer: Correlation with outcome variables. Mod Pathol2000; 13: 542–7.
122.
NakopoulouL., LazarisA.C., KavantzasN.. DNA topoisomerase II alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiol2000; 68: 137–43.
123.
JarvinenT.A., TannerM., RantanenV.. Amplification and deletion of topoisomerase II alpha associate with Erb-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Path2000; 156: 839–47.
124.
JarvinenT.A., TannerM., BarlundM., BorgA., IsolaJ.Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes, Chromosomes Cancer1999; 26: 142–50.
125.
JarvinenT.A., HolliK., KuukasjarviT., IsolaJ.Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer1998; 77: 2267–73.
126.
EderJ.P., ChanV.T., NgS.W.. DNA topoismoerase II alpha expression is associated with alkylating agent resistance. Cancer Res1995; 55: 6109–16.
127.
Di LeoA., GancbergD., LarsimontD.. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res2002; 8: 1107–16.
128.
CoonJ.S., MarcusE., Gupta-BurtS.. Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res2002; 8: 1061–7.
129.
MatsumotoY., TakanoH., KunishioK., NagaoS., FojoT.Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines. Jpn J Cancer Res2001; 92: 1133–7.
130.
HoldenJ.A., TownsendJ.J.DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Mod Pathol1999; 12: 1094–100.
131.
RoymansD., VissenbergK., De JongheC.. Identification of the tumor metastasis suppressor Nm23-H1/Nm23-R1 as a constituent of the centrosome. Exp Cell Res2001; 262: 145–53.
132.
PostelE.H., AbramczykB.M., LevitM.N., KyinS.Catalysis of DNA cleavage and nucleoside triphosphate synthesis by NM23-H2/NDP kinase share an active site that implies a DNA repair function. Proc Natl Acad Sci USA2000; 97: 14194–9.
133.
WalletV., MutzelR., TrollH.. Dictyostelium nucleoside diphosphate kinase highly homologous to Nm23 and Awd proteins involved in mammalian tumor metastasis and Drosophila development. J Natl Cancer Inst1990; 82: 1199–202.
134.
SteegP.S., BevilacquaG., KopperL., ThorgeirssonU.P., TalmadgeJ.E., LiottaL.A.Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst1988; 80: 200–4.
135.
CaligoM.A., CipolliniG., Cope Di ValromitaA., BistocchiM., BevilacquaG.Decreasing expression of NM23 gene in metastatic murine mammary tumors of viral etiology (MMTV). Anticancer Res1992; 12: 969–73.
136.
SuZ.Z., AustinN., ZimmerS.G., FisherP.B.Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells. Oncogene1993; 8: 1211–9.
137.
LakshmiM.S., ParkerC., SherbetG.V.Metastasis associated MTS1 and NM23 genes affect tubulin polymerisation in B16 melanomas: a possible mechanism of their regulation of metastatic behaviour of tumours. Anticancer Res1993; 13: 299–303.
138.
MacDonaldN.J., DeLaRosaA., SteegP.S.The potential roles of nm23 in cancer metastasis and cellular differentiation. Int J Cancer1995; 31A: 1096–100.
139.
MaoH., LiuH., FuX., FangZ., AbramsJ., WorshamM.J.Loss of nm23 expression predicts distal metastasis and poorer survival for breast cancer. Int J Oncol2001; 18: 587–91.
140.
ChenS.L., WuY.S., ShiehH.Y., YenC.C., ShenJ.J., LinK.H.P53 is a regulator of the metastasis suppressor gene Nm23-H1. Mol Carcinog2003; 36: 204–14.
141.
BabaH., UranoT., OkadaK.. Two isotypes of murine nm23/nucleoside diphosphate kinase, nm23-M1 and nm23-M2, are involved in metastatic suppression of a murine melanoma line. Cancer Res1995; 55: 1977–81.
142.
FukudaM., IshiiA., YasutomoY.. Decreased expression of nucleoside diphosphate kinase alpha isoform, an nm23-H2 gene homolog, is associated with metastatic potential of rat mammary-adenocarcinoma cells. Int J Cancer1996; 65: 531–7.
143.
LeoneA., FlatowU., VanHoutteK., SteegP.S.Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity. Oncogene1993; 8: 2325–33.
144.
KantorJ.D., McCormickB., SteegP.S., ZetterB.R.Inhibition of cell motility after nm23 transfection of human and murine tumor cells. Cancer Res1993; 53: 1971–3.
145.
MacDonaldN.J., FreijeJ.M., StrackeM.L., ManrowR.E., SteegP.S.Site-directed mutagenesis of nm23-H1. Mutation of proline 96 or serine 120 abrogates its motility inhibitory activity upon transfection into human breast carcinoma cells. J Biol Chem1996; 271: 25107–16.
146.
SauerT., FuruI., BerakiK., JebsenP.W., OrmerodE., NaessO.NM23 protein expression in fine-needle aspirates from breast carcinoma: Inverse correlation with cytologic grading, lymph node status and ploidy. Cancer1998; 84: 109–14.
147.
NiuY., FuX., LvA., FanY., WangY.Potential markers predicting distant metastasis in axillary node-negative breast carcinoma. Int J Cancer2002; 98: 754–60.
148.
HartsoughM.T., SteegP.S.Nm23-H1: genetic alterations and expression patterns in tumor metastasis. Am J Hum Genet1998; 63: 6–10.
149.
ForusA., D'AngeloA., HenriksenJ.. Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas - a possible mechanism for altering nm23-H1 activity. Oncogene2001; 20: 6881–90.
150.
HanS., YunI.J., NohD.Y., ChoeK.J., SongS.Y., ChiJ.G.Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein. J Surg Oncol1997; 65: 22–7.
151.
BrownP.D.Matrix metalloproteinase inhibitors. Breast Cancer Res Treat1998; 52: 125–36.
152.
OpdenakkerG., Van DammeJ.Chemotactic factors, passive invasion and metastasis of cancer cells. Immunol Today1992; 13: 463–4.
153.
PontonA., CoulombeB., SkupD.Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. Cancer Res1991; 51: 2138–43.
154.
GohjiK., FujimotoN., HaraI.. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer1998; 79: 96–101.
155.
RhaS.Y., YangW.I., KimJ.H.. Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep1998; 5: 875–9.
156.
HanemaaijerR., VerheijenJ.H., MaguireT.M.. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer2000; 86: 204–7.
157.
ZuckerS., LysikR.M., ZarrabiM.H., MollU.M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res1993; 53: 140–6.
158.
MacDougallJ.R., MatrisianL.M.Matrix metalloproteinases in the pathogenesis of breast cancer. In: BowcockA.M., ed. Breast cancer: Molecular genetics, pathogenesis, and therapeutics.Totowa, NJ: Humana Press Inc, 1998.
159.
LiottaL.A., TryggvasonK., GarbisaS., HartI., FoltzC.M., ShafieS.Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature1980; 284: 67–8.
160.
FingletonB., MatrisianL.M.Metalloproteinases in cancer. In: ClendeninnN.J., AppeltK., eds. Cancer drug discovery and development: Matrix metalloproteinase inhibitors in cancer therapy.Totowa, NJ: Humana Press Inc, 1998; 85–112.
161.
HalakaA.N., BunningR.A., BirdC.C., GibsonM., ReynoldsJ.J.Production of collagenase and inhibitor (TIMP) by intracranial tumors and dura in vitro. J Neurosurg1983; 59: 461–6.
162.
HicksN.J., WardR.V., ReynoldsJ.J.A fibrosarcoma model derived from mouse embryo cells: growth properties and secretion of collagenase and metalloproteinase inhibitor (TIMP) by tumour cell lines. Int J Cancer1984; 33: 835–44.
KitsonR.P., AppasamyP.M., NannmarkU., AlbertssonP., GabauerM.K., GoldfarbR.H.Matrix metalloproteinases produced by rat IL-2-activated NK cells. J Immunol1998; 160: 4248–53.
165.
SounniN.E., DevyL., HajitouA.. MT1-MMP expression promotes tumor growth and angiogenesis through an upregulation of VEGF expression. FASEB J2002; 16: 555–64.
166.
MonteagudoC., MerinoM.J., San-JuanJ., LiottaL.A., Stetler-StevensonW.G.Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Path1990; 136: 585–92.
167.
KossakowskaA.E., HuchcroftS.A., UrbanskiS.J., EdwardsD.R.Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer1996; 73: 1401–8.
168.
PoletteM., ClavelC., CockettM., Girod de BentzmannS., MurphyG., BirembautP.Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion Metastasis1993; 13: 31–7.
169.
BiswasC., ZhangY., DeCastroR.. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin super-family. Cancer Res1995; 55: 434–9.
170.
HimelsteinB.P., Canete-SolerR., BernhardE.J., MuschelR.J.Induction of fibroblast 92 kDa gelatinase/type IV collagenase expression by direct contact with metastatic tumor cells. J Cell Sci1994; 107: 477–86.
171.
Sheen-ChenS.M., ChenH.S., EngH.L., SheenC.C., ChenW.J.Serum levels of MMP2 in patients with breast cancer. Cancer Lett2001; 173: 79–82.
172.
StephensR.W., BrunnerN., JanickeF., SchmittM.The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat1998; 52: 99–111.
173.
DuffyM.J., O'GradyP., DevaneyD., O'SiorainL., FennellyJ.J., LijnenH.J.Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer1988; 62: 531–3.
174.
FrandsenT.L., Holst-HansenC., NielsenB.S.. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Cancer Res2001; 61: 532–7.
175.
HildenbrandR., DilgerI., HorlinA., StutteH.J.Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer. Pathol Res Pract1995; 191: 403–9.
176.
PedersenA.N., ChristensenI.J., StephensR.W.. The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. Cancer Res2000; 60: 6927–34.
177.
JanickeF., PacheL., SchmittM., UlmK., ThomssenC., PrechtlA., GraeffH.Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res1994; 54: 2527–30.
178.
FoekensJ.A., BuesseckerF., PetersH.A.. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res1995; 55: 1423–7.
179.
PachecoM.M., NishimotoI.N., Mourao-NetoM., MantovaniE.B., BrentaniM.M.Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its receptor in breast cancer as measured by Northern blot analysis. Int J Biol Markers2001; 16: 62–8.
180.
AlboD., BergerD.H., RothmanV.L., TuszynskiG.P.Role of urokinase plasminogen activator receptor in thrombospondin-1 mediated tumor cell invasion. J Surg Res1999; 82: 331–8.
181.
AbazaM.S., NarayanR.K., AtassiM.Z.Anti-urokinase-type plasminogen activator monoclonal antibodies inhibit the proliferation of human breast cancer cell lines in vitro. Tumour Biol1998; 19: 229–37.
182.
FersisN., KaufmannM., KramerM.D., WittmannG., WallwienerD., BastertG.Prognostic significance of plasminogen activator inhibitor-1 (PAI-1) in primary breast carcinoma. Geburtshilfe Frauenheilkd1996; 56: 28–34.
183.
SlivaD., EnglishD., LyonsD., FloydF.P.Protein kinase C induces motility of breast cancers by upregulating secretion of uPA through activation of AP-1 and NF-kappaB. Biochem Biophys Res Commun2002; 290: 552–7.
184.
SieuwertsA.M., KlijnJ.G., Henzen-LogmansS.C., FoekensJ.A.Cytokine-regulated urokinase-type-plasminogen-activator (uPA) production by human breast fibroblasts in vitro. Breast Cancer Res Treat1999; 55: 9–20.
185.
DunnS.E., TorresJ.V., OhJ.S., CykertD.M., BarrettJ.C.Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase. Cancer Res2001; 61: 1367–74.
186.
EvansD.M., Sloan-StakleffK.D.Maximum effect of urokinase plasminogen activator inhibitors in the control of invasion and metastasis of rat mammary cancer. Invasion Metastasis1998–99; 18: 252–60.
187.
AlboD., RothmanV.L., RobertsD.D., TuszynskiG.P.Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br J Cancer2000; 83: 298–306.
188.
XingR.H., RabbaniS.A.Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation. Int J Cancer1999; 81: 443–50.
189.
HarbeckN., AltU., BergerU.. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res2001; 7: 2757–64.
190.
JanickeF., PrechtlA., ThomssenC.. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst2001; 93: 913–20.
191.
BillgrenA.M., RutqvistL.E., JohanssonH., HagerstromT., SkoogL.The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment benefit with adjuvant tamoxifen. Eur J Cancer2000; 36: 1374–80.
192.
HarbeckN., KatesR.E., SchmittM.Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol2002; 20: 1000–7.
193.
LookM.P., van PuttenW.L., DuffyM.J.. Pooled analysis of prognostic impact of urokinase type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst2002; 94: 116–28.
194.
IshikawaN., EndoY., SasakiT.Inverse correlation between mRNA expression of plasminogen activator inhibitor-2 and lymph node metastasis in human breast cancer. Jpn J Cancer Res1996; 87: 480–7.
195.
EvansD.M., LinP.L.Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor. Am Surg1995; 61: 692–6.
196.
DugganC., KennedyS., KramerM.D.. Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer1997; 76: 622–7.
197.
SchrohlA.S., PedersenA.N., JensenV.. Tumour tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in breast cancer. Mol Cell Proteomics2003, 2: 164–72.
198.
RileyL.B., LangeM.K., BrowneR.J.. Analysis of cathepsin D in human breast cancer: usefulness of the processed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients. Breast Cancer Res Treat2000; 60: 173–9.
199.
TandonA.K., ClarkG.M., ChamnessG.C., McGuireW.L.Association of the 323/A3 surface glycoprotein with tumor characteristics and behavior in human breast cancer. Cancer Res1990; 50: 3317–21.
200.
Gonzalez-VelaM.C., GarijoM.F., FernandezF., BueltaL., Val-BernalJ.F.Cathepsin D in host stromal cells is associated with more highly vascular and aggressive invasive breast carcinoma. Histopath1999; 34: 35–42.
201.
WangF., SamudioI., SafeS.Transcriptional activation of cathepsin D gene expression by 17beta-estradiol: mechanism of aryl hydrocarbon receptor-mediated inhibition. Mol Cell Endocrinol2001; 172: 91–103.
202.
TetuB., BrissonJ., LapointeH., WangC.S., BernardP., BlanchetteC.Cathepsin D expression by cancer and stromal cells in breast cancer: an immunohistochemical study of 1348 cases. Breast Cancer Res Treat1999; 55: 137–47.
203.
LetoG., GebbiaN., RausaL., TumminelloF.M.Cathepsin D in the malignant progression of neoplastic diseases (review). Anticancer Res1992; 12: 235–40.
204.
RochefortH.Cathepsin D in breast cancer. Breast Cancer Res Treat1990; 16: 3–13.
205.
RochefortH., GarciaM., GlonduM.. Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin Chim Acta2000; 291: 157–70.
206.
VetvickaV., VetvickovaJ., HilgertI., VoburkaZ., FusekM.Analysis of the interaction of procathepsin D activation peptide with breast cancer cells. Int J Cancer1997; 73: 403–9.
207.
GaciZ., Bouin-PineauM.H., GaciM., DabanA., IngrandP., MetayeT.Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors. Int J Oncol2001; 18: 793–800.
208.
JahkolaT., ToivonenT., von SmittenK., VirtanenI., WaseniusV.M., BlomqvistC.Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors. Br J Cancer1999; 80: 167–74.
209.
KuteT.E., Grondahl-HansenJ., ShaoS.M., LongR., RussellG., BrunnerN.Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat1998; 47: 9–16.
210.
SolomayerE.F., DielI.J., MeybergG.C.. Prognostic relevance of cathepsin D detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Breast Cancer Res Treat1998; 49: 145–54.
211.
FoekensJ.A., LookM.P., Bolt-de VriesJ.. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer1999; 79: 300–7.
212.
LahT.T., CercekM., BlejecA.. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators. Clin Cancer Res2000; 6: 578–84.
213.
XingR., AddingtonA.K., MasonR.W.Quantification of cathepsins B and L in cells. Biochem J1998; 332(Pt 2): 499–505.
214.
MaguireT.M., SheringS.G., DugganC.M., McDermottE.W., O'HigginsN.J., DuffyM.J.High levels of cathepsin B predict poor outcome in patients with breast cancer. Int J Biol Markers1998; 13: 139–44.
215.
NicosiaR.F.What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?Am J Path1998; 153: 11–5.
216.
LeungD.W., CachianesG., KuangW.J., GoeddelD.V., FerraraN.Vascular endothelial growth factor is a secreted angiogenic mitogen. Science1989; 246: 1306–9.
217.
FolkmanJ., HanahanD.Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp1991; 22: 339–47.
218.
PlouetJ., SchillingJ., GospodarowiczD.Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J1989; 8: 3801–6.
219.
PriceD.J., MiralemT., JiangS., SteinbergR., AvrahamH.Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling in breast cancer. Cell Growth Differ2001; 12: 129–35.
ConnollyD.T., OlanderJ.V., HeuvelmanD.. Human vascular permeability factor. Isolation from U937 cells. J Biol Chem1989; 264: 20017–24.
222.
SalvenP., PerhoniemiV., TykkaH., MaenpaaH., JoensuuH.Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat1999; 53: 161–6.
223.
GaspariniG.Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist2000; (5 Suppl 1): 37–44.
224.
LissoniP., MaluganiF., BonfantiA.. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and en-dothelin-1. J Biol Regul Homeost Agents2001; 15: 140–4.
225.
PidgeonG.P., BarrM.P., HarmeyJ.H., FoleyD.A., Bouchier-HayesD.J.Vascular endothelial growth factor (VEGF) up-regulates bcl-2 and inhibits apoptosis in human and murine mammary adenocarinoma cells. Br J Cancer2001; 85: 273–8.
226.
LewisJ.S., LandersR.J., UnderwoodJ.C., HarrisA.L., LewisC.E.Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol2000; 192: 150–8.
227.
KumarR., Yarmand-BagheriR.The role of HER2 in angiogenesis. Semin Oncol2001; 28(5 Suppl 16): 27–32.
228.
DonovanD., HarmeyJ.H., ToomeyD., OsborneD.H., RedmondH.P., Boucher-HaysD.J.TGF beta-1 regulation of VEGF production by breast cancer cells. Ann Surg Oncol1997; 4: 621–7.
229.
KurizakiT., ToiM., TominagaT.Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol Rep1998; 5: 673–7.
230.
BenoyI., SalgadoR., ColpaertC., WeytjensR., VermeulenP.B., DirixL.Y.Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer2002; 2: 311–5.
231.
DiasS., BoydR., BalkwillF.IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer1998; 78: 361–5.
232.
HajitouA., SounniN.E., DevyL.. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res2001; 61: 3450–7.
233.
ToiM., BandoH., OgawaT., MutaM., HornigC., WeichH.A.Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer2002; 98: 14–8.
234.
BorgstromP., GoldD.P., HillanK.J., FerraraN.Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res1999; 19: 4203–14.
235.
ImS.A., KimJ.S., Gomez-ManzanoC.. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br J Cancer2001; 84: 1252–7.
236.
OlofssonB., PajusolaK., von EulerG., ChilovD., AlitaloK., ErikssonU.Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J Biol Chem1996; 271: 19310–7.
237.
GunninghamS.P., CurrieM.J., HanC.. VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. J Pathol2001; 193: 325–32.
238.
KurebayashiJ., OtsukiT., KunisueH.. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res1999; 90: 977–81.
239.
KukkE., LymboussakiA., TairaS.. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development1996; 122: 3829–37.
240.
SalvenP., LymboussakiA., HeikkialP.. Vascular endothelial growth facotrs VEGF-B and VEGF-C are expressed in human tumors. Am J Path1998; 153: 103–8.
241.
KarpanenT., EgebladM., KarkkainenM.J.. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res2001; 61: 1786–90.
242.
KinoshitaJ., KitamuraK., KabashimaA., SaekiH., TanakaS., SugimachiK.Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat2001; 66: 159–64.
243.
SkobeM., HawighorstT., JacksonD.G.. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med2001; 7: 192–8.
244.
NakamuraY., YasuakaH., TsujimotoM.. Clinicopathological significance of vascular endothelial growth factor-c in breast carcinoma with long term follow-up. Mod Pathol2003; 16: 309–14.
245.
AchenM.G., JeltschM., KukkE.. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA1998; 95: 548–53.
246.
KahnH.J., YangL.Y., BlondalJ.. RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients: correlation with established prognostic parameters. Breast Cancer Res Treat2000; 60: 143–51.
247.
AertsJ., WyendaeleW., ParidaensR.. A real time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood. Ann Oncol2001; 12: 439–61.
248.
BeroisN., VarangotM., AizenB.. Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1 and CEA using RT-PCR. Eur J Cancer2000; 36: 717–23.
249.
BartekJ., Taylor-PapadimitriouJ., MillerN., MillisR.Patterns of expression of keratin 19 as detected with monoclonal antibodies in human breast tissues and tumours. Int J Cancer1985; 36: 299–306.
250.
RoseM.G., BurtnessB.A., CrouchJ.Y., MarshJ.C., ReissM., HoweJ.G.Detection of circulating breast cancer cells by reverse transcription-polymerase chain reaction (RT-PCR) for cytokeratin 19 (CK19) in patients with breast cancer. Proc Annu Meet Soc Clin Oncol1997; 16: A662.
251.
ZhongX.Y., KaulS., DielI., EichlerA., BastertG.Analysis of sensitivity and specificity of cytokeratin 19 reverse transcriptase/polymerase chain reaction for detection of occult breast cancer in bone marrow and leukapheresis products. J Cancer Res Clin Oncol1999; 125: 286–91.
252.
SilvaJ.M., DominguezG., SilvaJ.. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res2001; 7: 2821–5.
253.
YangD.C., HeadJ.F., JiangX.P., ElliottR.L.Expression of cytokeratin 19 mRNA is associated with differentiation of human breast tumors. Proc Am Soc Clin Oncology1998; abstract 2198.
254.
FlemingT.P., WatsonM.A.Mammaglobin, a breast-specific gene, and its utility as a marker for breast cancer. Ann NY Acad Sci2000; 923: 78–89.
255.
ColpittsT.L., Billing-MedelP., FriedmanP.. Mammaglobin is found in breast tissue as a complex with bu101. Biochemistry2001; 40: 11048–59.
256.
WatsonM.A., DintzisS., DarrowC.M.. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res1999; 59: 3028–31.
257.
KataokaA., MoriM., SadanagaN.. RT-PCR detection of breast cancer cells in sentinel lymph nodes. Int J Oncol2000; 16: 1147–52.
258.
OokaM., SakitaI., FujiwaraY.. Selection of mRNA markers for detection of lymph node micrometastases in breast cancer patients. Oncol Rep2000; 7: 561–6.
259.
GrunewaldK., HaunM., UrbanekM.. Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermal-growth-factor receptor and cytokeratin-19. Lab Invest2000; 80: 1071–7.
260.
ZachO., KasparuH., KriegerO., HehenwarterW., GirschikofskyM., LutzD.Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J Clin Oncol1999; 17: 2015–9.
261.
OokaM., TamakiY., SakitaI.. Bone marrow micrometastases detected by RT-PCR for mammaglobin can be an alternative prognostic factor of breast cancer. Breast Cancer Res Treat2001; 67: 169–75.
262.
ZachO., KasparuH., WagnerH., KriegerO., LutzD.Detection of mammaglobin mRNA as a marker for circulating tumor cells in breast carcinoma. Acta Med Austriaca2000; 27: 13–5.
263.
HoughtonR.L., DillonD.C., MoleshD.A.. Transcriptional complementarity in breast cancer: Application to detection of circulating tumor cells. Mol Diagn2001; 6: 79–91.
264.
ScibettaA.G., AlbaneseI., MorrisJ.. Regulation of MUC1 expression in human mammary cell lines by the c-ErbB2 and ras signaling pathways. DNA Cell Biol2001; 20: 265–74.
265.
RahnJ.J., DabbaghL., PasdarM., HughJ.C.The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer2001; 91: 1973–82.
266.
WesselingJ., van der ValkS.W., VosH.L., SonnenbergA., HilkensJ.Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol1995; 129: 255–65.
267.
DuffyM.J., SheringS., SherryF., McDermottE., O'HigginsN.CA 15–3: a prognostic marker in breast cancer. Int J Biol Markers2000; 15: 330–3.
268.
GionM., MioneR., LeonA.E.. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer2001; 37: 355–63.
269.
BriasoulisE., AndreopoulouE., TolisC F.. G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. Cancer2001; 91: 909–17.
270.
KallioniemiO.P., OksaH., AaranR.K., HietanenT., LehtinenM., KoivulaT.Serum CA15-3 assay in the diagnosis and follow-up of breast cancer. Br J Cancer1988; 58: 213–5.
271.
MiserezA.R., GunesI., Muller-BrandJ., WaltherE., FridrichR., MackeH.Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3. Eur J Cancer1991; 27: 126–31.
272.
BarakV., CarlinD., SulkesA., TrevesA., BiranS.CA15-3 serum levels in breast cancer and other malignancies-correlation with clinical course. Isr J Med Sci1988; 24: 623–7.
273.
McLaughlinR., McGrathJ., GrimesH., GivenH.F.The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patients with breast cancer. Int J Biol Markers2000; 15: 340–2.
274.
WojtackiJ., Dziewulska-BokiniecA., SkokowskiJ., CiesielskiD.Evaluation of CA 15-3 tumor marker in the diagnosis of breast cancer. A pilot study. Neoplasma1994; 41: 213–6.
275.
DnistrianA.M., SchwartzM.K., GreenbergE.J., SmithC.A., SchwartzD.C.CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. Clin Chim Acta1991; 200: 81–93.
276.
CanizaresF., SolaJ., PerezM.. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumour Biol2001; 22: 273–81.
277.
HayesD.F., ZurawskiV.R.Jr., KufeD.W.Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol1986; 4: 1542–50.
278.
SafiF., KohlerI., RottingerE., SuhrP., BegerH.G.Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers1989; 4: 207–14.
279.
ColomerR., RuibalA., GenollaJ.. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat1989; 13: 123–33.
280.
EinarssonR., LindmanH., BerghJ.Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients. Anticancer Res2000; 20: 5089–93.
281.
KumpulainenE.J., KeskikuruR.J., JohanssonR.T.Serum tumor CA 15.3 and stage are the most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat2002; 76: 95–102.
282.
HouM.F., ChenY.L., TsengT.F.. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer. Kaohsiung J Med Sci1999; 15: 520–8.
283.
LufterD., RichterA., GuntherS.. A comparison of bone-related biomarkers and CA27.29 to assess response to treatment of osseous metastatic breast cancer. Anticancer Res2000; 20: 5099–105.
284.
SnijdewintF.G., von Mensdorff-PouillyS., Karuntu-WanamartaA.H.. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer2001; 93: 97–106.
285.
HallJ.M., FriedmanL., GuentherC.. Closing in on a breast cancer gene on chromosome 17q. Am J Hum Genet1992; 50: 1235–42.
286.
WoosterR., NeuhausenS.L., MangionJ.. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science1994; 265: 2088–90.
287.
YangX., LippmanM.E.BRCA1 and BRCA2 in breast cancer. Breast Cancer Res Treat1999; 54: 1–10.
288.
GiordanoS.H., BuzdarA.U., HortobagyiG.N.Breast cancer in men. Ann Intern Med2002; 137: 678–87.
ScullyR., AndersonS.F., ChaoD.M.. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci USA1997; 94: 5605–10.
291.
YardenR.I., Pardo-ReoyoS., SgagiasM., CowanK.H., BordyL.C.BRCA1 regulates the G2/M checkpoint by activating Chk1 upon DNA damage. Nat Genet2002; 30: 285–9.
292.
ThompsonM.E., JensenR.A., ObermillerP.S., PageD.L., HoltJ.T.Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet1995; 9: 444–50.
293.
RaoV.N., ShaoN., AhmadM., ReddyE.S.Anti-sense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts. Oncogene1996; 12: 523–8.
294.
FanS., WangJ., YuanR.. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science1999; 284: 1354–6.
295.
LiuY., WestS.C.Distinct functions of BRCA1 and BRCA2 in double-strand break repair. Breast Cancer Res2002; 4: 9–13.
296.
SmithS.A., EastonD.F., EvansD.G., PonderB.A.Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet1992; 2: 128–31.
297.
MagdinierF., RibierasS., LenoirG.M., FrappartL., DanteR.Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region. Oncogene1998; 17: 3169–76.
298.
IshitobiM., MiyoshiY., AndoA.. Association of BR-CA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis. Clin Cancer Res2003; 9: 1376–80.
299.
StrattonM.R., FordD., NeuhasenS.. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet1994; 7: 103–7.
300.
VielhP., ChevillardS., MosseriV., DonatiniB., MagdelénatH.Ki67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors. Am J Clin Pathol1990; 94: 681–6.
301.
BarnardN.J., HallP.A., LemoineN.R., KadarN.Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol1987; 152: 287–95.
302.
WeidnerN., MooreDHII, VartanianR.Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel “paraffin”-reactive MIB1 antibody. Hum Pathol1994; 25: 337–42.
303.
D'ErricoA., GarbisaS., LiottaL.A., CastronovoV., Stetler-StevensonW.G., GrigioniW.F.Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Mod Pathol1991; 4: 239–46.
304.
SneigeN., WangJ., BakerB.A., KrishnamurthyS., MiddletonL P.Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol2002; 15: 1044–50.
305.
DacicS., KounelisS., KouriE., JonesM.W.Immunohistochemical profile of cystosarcoma phyllodes of the breast: a study of 23 cases. Breast J2002; 8: 376–81.
306.
DervanP.A., GilmartinL.G., LoftusB.M., CarneyD.N.Breast carcinoma kinetics. Argyrophilic nucleolar organizer region counts correlate with Ki67 scores. Am J Clin Pathol1989; 92: 401–7.
307.
BouzubarN., WalkerK.J., GriffithsK.. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer1989; 59: 943–7.
308.
MidullaC., PisaniT., De IorioP.. Cytological analysis and immunocytochemical expression of Ki67 and Bcl-2 in breast proliferative lesions. Anticancer Res2002; 22: 1341–5.
309.
CharpinC., AndracL., LavautM.N.. Image cytometry of aneuploidy, growth fraction (MoAb Ki-67) and hormone receptors (ER, PR) immunocytochemical assays in breast carcinomas. Anal Cell Pathol1990; 2: 357–71.
310.
ClarkG.M., DresslerL.G., OwensM.A., PoundsG., OldakerT., McGuireW.L.Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med1989; 320: 627–33.
311.
MakrisA., PowlesT.J., DowsettM., AllredC.p53 protein overexpression and chemosensitivity in breast cancer. Lancet1995; 345: 1181–2.
312.
O'ReillyS.M., CamplejohnR.S., RubensR.D., RichardsM.A.DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer1992; 28: 681–3.
313.
HenselM., SchneeweissA., SinnH.P.. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int J Cancer2002; 100: 290–6.
314.
MillerW.R., DixonJ.M., MacfarlaneL., CameronD., AndersonT.J.Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer2002; 39: 462–8.
315.
FaneyteI.F., SchramaJ.G., PeterseJ.L., RemijnseP.L., RodenhuisS., van de VijverM.J.Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer2003; 88: 406–12.
316.
DowsettM.Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res2003; 9(1 Pt 2): 502S–10S.
317.
Wang-RodriguezJ., CrossK., GallagherS., DjahanbanM., ArmstrongJ.M., WiednerN., ShapiroD.H.Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol2002; 15: 853–61.
318.
SilvestriniR., BeniniE., VeneroniS.. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol1996; 14: 1604–10.
319.
KrajewskiS., KrajewskaM., TurnerB.C.. Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer1999; 6: 29–40.
320.
ZhangG.J., KimijimaI., TsuchiyaA., AbeR.The role of bcl-2 expression in breast carcinomas (Review). Oncol Rep1998; 5: 1211–6.
321.
GaspariniG., BarbareschiM., DoglioniC.. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res1995; 1: 189–98.
322.
DaidoneM.G., LuisiA., VeneroniS., BeniniE., SilvestriniR.Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. Endocr Relat Cancer1999; 6: 61–8.
323.
JoensuuH., PylkkanenL., ToikkanenS.Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol1994; 145: 1191–8.
324.
DaidoneM.G., VeneroniS., BeniniE.. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int J Cancer1999; 84: 580–6.
325.
DaidoneM.G., LuisiA., MartelliG.. Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women. Br J Cancer2000; 82: 270–7.
326.
AshburnerM., BallC.A., BlakeJ.A.. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature Genet2000; 25: 25–9.
327.
KorschingE., PackeisenJ., AgelopoulosK.. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest2002; 82: 1525–33.
328.
MakrisA., AllredD.C., PowlesT.J.. Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat1997; 44: 65–74.
329.
GaspariniG.Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist2000; 5(Suppl 1): 37–44.
330.
BiroccioA., CandiloroA., MottoleseM.. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB J2000; 14: 652–60.
331.
ZolotaV., GerokostaA., MelachrinouM., KomineaA., AletraC., ScopaC.D.Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast. Anticancer Res1999; 19: 3269–74.
332.
BottiniA., BerrutiA., BersigaA.. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer. Clin Cancer Res2002; 8: 1816–21.
